GLP-1 medications linked to a lower risk of dementia and addiction but higher risk of kidney, pancreatic, and ...

The media queen also confessed that she was reluctant to take a GLP-1 drug because she felt it was “the easy way out.” That ...

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat ...

Concern is growing among Democrats after President Donald Trump reversed some of the former president’s executive orders, ...

Biopharma executives shared their thoughts on the potential impacts of the new administration; Annalee Armstrong recaps JPM ...

Average price per insulin unit dropped 42%, from $0.33 in 2019 to $0.19 in mid-2024 -- the lowest average recorded in a ...

The benefits of taking GLP-1 agonists seem to outweigh the risks, at least when taken for approved uses, according to an ...

About 140,400 obese patients in Massachusetts were prescribed medications like Wegovy and Zepbound in 2024, a 255 percent ...

Miracle drug innovations — such as those that sparked the meteoric rise of Wegovy and Zepbound — could come every couple of ...

The analysts expect launches of medicines including Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy to help add $20 billion to the value of the market in a decade. After a fallow period ...

AS HOLIDAY TREATS GIVE WAY TO NEW YEAR’S RESOLUTIONS, the names of GLP-1 weight-loss drugs like Ozempic and Wegovy will be on millions of lips this January—in addition to any leftover fruitcake, ...